Nareg Sagherian
About Nareg Sagherian
Nareg Sagherian serves as the Vice President and Global Head of Investor Relations and Corporate Communications at Evolus (NASDAQ: EOLS) since 2023. He has extensive experience in investor relations, having held various roles in organizations such as Intercept Pharmaceuticals and the Biotechnology Innovation Organization.
Work at Evolus
Nareg Sagherian serves as the Vice President, Global Head of Investor Relations and Corporate Communications at Evolus, a position he has held since 2023. His role involves managing investor relations and corporate communications for the company, which is publicly traded on NASDAQ under the ticker symbol EOLS. He is based in Newport Beach, California.
Education and Expertise
Nareg Sagherian has an extensive educational background. He earned a Master of Business Administration (MBA) from the University of Virginia Darden School of Business, graduating in the top 10% of his cohort and receiving the Faculty Award for Academic Excellence. He also holds a Master of Science (M.S.) in Banking and Finance from The Johns Hopkins University - Carey Business School, as well as a Master of Science (M.S.) in Medical Clinical Sciences/Biomedical Sciences from Wayne State University School of Medicine. Additionally, he has completed a Graduate Diploma in Legislative Affairs from Georgetown University and a Graduate Diploma in Investments and Securities from The Johns Hopkins University.
Professional Background
Nareg Sagherian has held various roles in investor relations and corporate communications across multiple organizations. Prior to his current role at Evolus, he worked at Intercept Pharmaceuticals as Executive Director, Head of Global Investor Relations and Corporate Affairs. He also served as Managing Director at FTI Consulting, focusing on capital markets and public affairs in the healthcare sector. His experience includes positions at the U.S. Department of the Treasury and the U.S. Small Business Administration, where he contributed to international economic policy and investment strategies.
Key Achievements
During his career, Nareg Sagherian played a significant role in the acquisition of Intercept Pharmaceuticals by AlfaSigma S.p.A. for approximately $800 million. He also served as the primary liaison between the Biotechnology Innovation Organization and its stakeholders, representing over $500 billion in capital. His expertise includes developing and executing client engagements related to mergers and acquisitions, initial public offerings (IPOs), and shareholder activism.